Category Archives: HSA

Henan Proposes Standardizing and Consolidating Medical Services Pricing Items Across Four Clinical Categories – Public Consultation Open Through 17 September, With Parallel Cancellation Lists

Zhengzhou, China – 11 Sep 2026 – The Henan Provincial Healthcare Security Administration has released for public comment its draft plan to standardize and consolidate medical services pricing items in four clinical categories – digestive system, vascular and lymphatic system, maxillofacial surgery, and general treatment – together with matching lists of price items proposed for cancellation in each category. The consultation, issued under the national pilot program for deepening medical service price reform (Yi Bao Fa [2021] No. 41), accepts written or scanned feedback before 17 September 2026.

Policy Milestone

ItemDetail
Issuing AgencyHenan Provincial Healthcare Security Administration – Department of Medical Commodity Pricing and Tender Procurement
Announcement Date11 Sep 2026
Policy BasisNHSA and seven other departments’ Notice on Issuing the Pilot Program for Deepening Medical Service Price Reform (Yi Bao Fa [2021] No. 41); NHSA project‑establishment guidelines for medical service price items
ScopeStandardization and consolidation of price items across digestive system; vascular & lymphatic system; maxillofacial surgery; general treatment categories
Dual StructureEight attachments: 4 consolidation drafts + 4 cancellation drafts (one pairing per category)
Comment DeadlineBefore 17 September 2026 – written submission or electronic scan, bearing organizational seal or personal signature
ContactTel: 0371‑69690434; Email: hnsybjjgzc@126.com

Standardization & Consolidation Framework

  • Two‑Track Restructuring: For each of the four categories, the Administration has prepared both a draft of standardized/consolidated price items (Attachments 1–4) and a draft list of price items proposed for cancellation (Attachments 5–8) – signaling a deliberate slimming of Henan’s fragmented local price‑item catalog.
  • Category Pairing: Vascular and lymphatic system services are handled together as a single consolidated category, alongside digestive system, maxillofacial surgery and general treatment items.
  • National Guidelines Alignment: The restructuring implements the NHSA’s project‑establishment guidelines (立项指南) for medical service price items – part of the nationwide campaign to unify locally defined, inconsistently named service items under standardized national categories.
  • Pricing Reform Pilot Lineage: The plan operationalizes the 2021 eight‑department price reform pilot framework, which shifted the policy focus from item‑by‑item price adjustment toward structural standardization of what hospitals may charge and bill.
  • Draft Content: Specific item names, mappings and price levels are set out in the eight attachments and were not disclosed in the public notice itself.

Public Consultation Requirements

  • Eligible Submitters: Any organization or individual.
  • Format: Comments must be submitted in writing or as electronic scans to the Administration’s Department of Medical Commodity Pricing and Tender Procurement.
  • Authentication: Submissions must bear the official seal of the organization or the personal signature of the submitter; feedback is due before 17 September 2026.

Market Impact & Outlook

  • Catalog Rationalization: Consolidation paired with explicit cancellation lists will compress Henan’s billable service menu, eliminating overlapping, outdated or fragmented charge items – a prerequisite for transparent, comparable pricing across hospitals.
  • Hospital Billing Impact: Providers will need to remap billing systems and internal charge masters to the new standardized items, with abolished items requiring migration to consolidated equivalents.
  • National Convergence Signal: As more provinces issue guideline‑based restructuring drafts, Henan’s move reinforces the trajectory toward nationally uniform medical service price items, reducing cross‑province variation in how identical procedures are named and priced.
  • Price‑Level Uncertainty: The notice covers item standardization and consolidation, not the setting of new price levels; any subsequent price adjustments would follow separate provincial processes – details not disclosed.
  • Tight Window: The roughly six‑day comment period suggests the Administration intends to finalize the restructured catalog on a compressed timeline.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization and implementation of Henan Province’s standardized and consolidated medical services pricing items. Actual outcomes may differ due to risks including public feedback, revisions to draft consolidation and cancellation lists, national guideline updates, and provincial implementation timing. The drafts remain subject to revision and do not constitute final policy.-China Health Reform Pulse

Policy Source: http://ylbz.henan.gov.cn/2026/09-11/3418603.html

Heilongjiang Releases Draft Payment Standards for Medical Insurance Medical Consumables (2026) – Public Consultation Open Through 16 September, Bone and Soft‑Tissue Implants in Scope

Harbin, China – 11 Sep 2026 – The Heilongjiang Provincial Healthcare Security Administration has published the draft “Heilongjiang Province Medical Insurance Medical Consumables Payment Standards (2026)” for public comment, a province‑wide framework that integrates and maps medical insurance consumables codes and sets reimbursement payment standards – prioritizing the classification, coding and universal generic name management of bone, cartilage and soft‑tissue implant consumables. The consultation window runs from 11 to 16 September 2026.

Policy Milestone

ItemDetail
Issuing AgencyHeilongjiang Provincial Healthcare Security Administration
DocumentHeilongjiang Province Medical Insurance Medical Consumables Payment Standards (2026) – Draft for Comments
Policy BasisNHSA Notice on Properly Carrying Out Payment Management of Medical Consumables under Basic Medical Insurance (Yi Bao Fa [2023] No. 23) and related documents
Core ContentIntegrated code mapping for insured medical consumables; establishment of payment standards (detailed schedules in the attachment)
Priority CategoryBone, cartilage and soft‑tissue implant consumables – classification & code and universal generic name management
Comment Period11–16 September 2026
Submission ChannelEmail to yyfwglc@163.com; telephone 0451‑88830031

Payment Standards Framework

  • Standardized Payment Management: The draft is designed to further regulate payment management of medical consumables covered by the province’s medical insurance programs and to improve the efficiency of insurance fund usage.
  • Code Integration & Mapping: The Administration will consolidate and map medical insurance consumables codes and set corresponding payment standards – aligning provincial reimbursement practice with national coding and universal generic name requirements.
  • Implant Focus: The notice specifically invokes management requirements for bone, cartilage and soft‑tissue implant consumables – a high‑value category long targeted by national and regional procurement and price‑governance efforts.
  • Detailed Standards: Category‑level and product‑level payment standard values are set out in the draft’s attachment and were not disclosed in the public notice itself.

Public Consultation Requirements

  • Timeline: Comments accepted from 11 September through 16 September 2026.
  • Format: Opinions and suggestions – with supporting reasons – must be submitted by email to the Provincial Healthcare Security Administration.
  • Authentication: Feedback materials must bear the official seal of the submitting organization or the authentic personal signature of an individual, and must include contact details; anonymous emails will not be accepted.

Market Impact & Outlook

  • Reimbursement Ceiling Signal: Codified provincial payment standards effectively set reimbursement reference ceilings for insured consumables in Heilongjiang, with hospitals and patients bearing costs above the standard – pressuring suppliers to align pricing accordingly.
  • Implant‑Category Focus: By foregrounding bone, cartilage and soft‑tissue implants, the draft extends the national playbook of coding uniformity plus payment standard governance to one of the highest‑spending consumable segments.
  • National Alignment: Anchored in Yi Bao Fa [2023] No. 23, the provincial framework keeps Heilongjiang synchronized with the NHSA’s push for standardized consumables payment management nationwide, reducing cross‑province reimbursement arbitrage.
  • Short Feedback Window: The six‑day consultation period suggests the Administration aims to finalize and implement the 2026 standards on a tight cycle ahead of the new year.
  • Next Steps: Final payment standard values, effective date and implementation mechanics will depend on the finalized document following the consultation – details not yet disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the finalization and implementation of the Heilongjiang Province Medical Insurance Medical Consumables Payment Standards (2026). Actual outcomes may differ due to risks including public feedback, adjustments to draft standards, national policy changes and provincial implementation timelines. The draft remains subject to revision and does not constitute final policy.-China Health Reform Pulse

Policy Source: https://ybj.hlj.gov.cn/ybj/c105387/202609/c00_31974724.shtml

Hunan Implements National Coronary Stent VBP Second‑Round Continuation Results – Province‑Wide Execution From 1 October 2026 With Red/Yellow Price Guardrails

Changsha, China – 09 Sep 2026 – The Hunan Provincial Healthcare Security Administration (Hunan Medical Insurance Bureau) has issued a formal notice (Xiang Yi Bao Han [2026] No. 37) to implement the selection results of the nationally organized second‑round continuation volume‑based procurement (VBP) of coronary stent medical consumables, mandating that all public medical institutions in the province – including military hospitals – purchase and use selected products at the awarded prices from 1 October 2026, with the procurement cycle running through 30 June 2029.

Regulatory Milestone

ItemDetail
Issuing AgencyHunan Provincial Healthcare Security Administration
DocumentXiang Yi Bao Han [2026] No. 37 (issued 9 Sep 2026)
Policy TypeProvincial implementation of national VBP second‑round continuation selection results
Product ScopeCoronary stent consumables – selected products per the attached national list
Effective Date1 October 2026 (province‑wide unified execution)
Procurement CycleThrough 30 June 2029; first contract year covers 1 Oct 2026 – 31 Dec 2027; agreements signed annually
Key DeadlinesSupplier registration & distribution setup on the Hunan Medical Procurement Platform by 30 Sep 2026; tripartite purchase‑sale agreements signed by 1 Nov 2026

Procurement Mechanism & Compliance Requirements

  • Participating Institutions: All public medical institutions (including military facilities) and all institutions that reported volumes are required to purchase and use selected products; other medical‑insurance‑contracted institutions are encouraged to participate.
  • Agreed Volumes: Annual contracted volumes are the quantities confirmed by hospitals in the procurement system (communicated separately to hospitals and winning suppliers). The first‑year volume is scaled at 15/12 of the annual agreement (rounded), reflecting the 15‑month initial contract period; non‑integer results are rounded.
  • Beyond‑Agreement Supply: Purchases exceeding the agreed volume must still be supplied by winning companies at the selected price until the end of the procurement cycle.
  • Platform‑Only Trading: All transactions must run through the Hunan Medical Procurement Platform; offline procurement, secondary price negotiation and any form of discount are strictly prohibited.
  • Usage Floor: Selected products must account for no less than 80% of total same‑category procurement and usage volume during the agreement period; hospitals may buy other price‑appropriate products only after fulfilling contracted volumes.
  • No Hidden Fees: Hospitals (including third‑party service providers) may not charge any additional fees for market entry, inventory or clinical use of selected stents, and may not block access citing cost control, product‑count limits, unreported volumes, quality deposits or distributor account caps.
  • Supply Responsibility: Winning companies are the first‑line responsible party for quality and supply, and must maintain emergency stockpiles and report capacity shortfalls to the provincial bureau in advance; prior distribution relationships are automatically cleared upon implementation. Non‑compliance (supply failure, quality defects) will be escalated to the Joint Procurement Office, with penalties, disqualification and credit‑system consequences applied.

Price Guardrails – Red/Yellow Label Monitoring

Under the “price‑procurement linkage” mechanism, non‑selected coronary stents listed on the platform at elevated prices will carry warning labels benchmarked to the highest selected price, with procurement risk alerts issued to hospitals:

Product CategoryYellow Label Threshold (≥1.8× highest selected price)Red Label Threshold (≥2.5× highest selected price)
Non‑selected coronary drug‑eluting alloy stents¥1,708 / unit¥2,372 / unit
Non‑selected coronary drug‑eluting stainless‑steel stents¥1,526 / unit¥2,120 / unit

Selected‑product awarded prices and company‑level results were not disclosed in the provincial notice (referenced to the national attachment list).

Market Impact & Outlook

  • Continuity Signal: The second‑round continuation locks the nationally pioneered coronary stent VBP framework in place through mid‑2029, extending price certainty for hospitals and winning manufacturers after the landmark first round that reset China’s stent market.
  • Pressure on Non‑Selected Products: The explicit red/yellow label price ceilings (1.8× / 2.5× the top awarded price) effectively cap how long premium‑priced non‑selected stents can compete in Hunan, pushing hospitals toward selected products and squeezing margin room for out‑of‑award brands.
  • Hospital Enforcement Teeth: Execution progress is subject to “monthly monitoring and annual evaluation,” and is written into medical‑insurance designated‑hospital agreement assessments; hospitals with serious lag, unfulfilled volumes or heavy use of high‑priced non‑selected products face contractual consequences.
  • Supplier Reset: Automatic clearing of prior distribution relationships forces winning companies to rebuild logistics coverage within weeks of the notice, while distributor performance (order response, delivery) becomes a compliance exposure for manufacturers.
  • National Alignment: The notice stipulates that any national policy adjustments during the cycle will be followed accordingly, keeping Hunan’s execution synchronized with the central healthcare security authority’s continuation‑procurement playbook.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding procurement execution timelines, contract volumes, supply arrangements and price‑monitoring enforcement for the coronary stent VBP continuation in Hunan Province. Actual outcomes may differ due to risks including national policy adjustments, supplier capacity and distribution readiness, hospital compliance dynamics, and quality or supply disruptions. Company‑level awarded prices and volumes are not disclosed in the provincial notice.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260910_34061201.html